Doctors, former patients warn of LASIK eye surgery dangers: ‘Biggest scam ever put on the American public'
The suicide of a 26-year-old Pennsylvania police officer over the after-effects of the popular eye surgery LASIK was not an isolated incident, with others saying it left them with agonizing and life changing symptoms, patients and doctors told The Post.
LASIK providers say the procedure is 95% to 99% safe, but one LASIK survivor said she had suicidal ideations for two years after her 'disastrous' surgery in 2000.
She also claimed to know of at least 40 people to have taken their own lives because they couldn't take constant pain and vision problems, developed after the procedure.
Advertisement
8 Ryan Kingerski, 26, died by suicide after undergoing LASIK surgery in 2024.
Family Handout
8 Tim and Stefanie Kingerski said Ryan suffered headaches, double vision, seeing dark spots and floaters — tiny spots that appear as streaks or cobweb-like shapes across a person's field of vision — after LASIK surgery.
CBS Pittsburgh
'I really didn't want to stick around at times, but I decided I would to get the word out about how dangerous this surgery can be,' Paula Cofer, 66, of Tampa, Fla., told The Post Wednesday.
Advertisement
'The LASIK lobby and the surgeons will tell you only one percent of patients have issues afterward. That's not true. There are multiple studies that indicate otherwise.
'The percentage of those with poor outcomes are in the double digits, not one percent. And they know it,' she claimed.
Since LASIK was approved by the Food and Drug Administration in 1999 over 10 million people in the US have undergone Laser Vision Correction, according to the medical journal Clinical Ophthalmology, which states between 700,000 and 800,000 people sign up for it each year.
Cofer runs the Lasik Complications Support Group on Facebook, one of numerous organizations on social media which have sprung up in response to LASIK procedures gone wrong.
Advertisement
8 Laser vision correction being carried out by a doctor.
Vadim – stock.adobe.com
'If you understand Lasik and what it does to the eyes and cornea, you realize you can't do it on a healthy eye and not expect complications,' Cofer said.
The procedure — Laser-Assisted In Situ Keratomileusis — reshapes the cornea of the eye.
'Not everyone has severe complications but a lot more people are suffering than you know. I got floaters, severe dry eyes, induced astigmatism and severe night vision problems,' said Cofer.
Advertisement
Ryan Kingerski, 26 — the cop who died by suicide after taking time off from the Penn Hills Police Department in Allegheny County, Penn. last August to undergo LASIK — had similar symptoms.
His grieving parents, Tim and Stefanie Kingerski, told CBS News this week about the hell their son went through after the procedure.
The Kingerskis said Ryan began suffering from headaches, double vision, seeing dark spots and floaters — tiny spots that appear as streaks or cobweb-like shapes across a person's field of vision, they said.
8 Paula Cofer, 66, started the Lasik Complications Support Group on Facebook to help others after suffering complications from her own procedure.
Courtesy of Paula Cofer
8 Fox 2 Detroit meteorologist Jessica Starr took her own life and left a note and videos explaining it was because of the complications she suffered after undergoing LASIK surgery.
Facebook
Ryan's parents told a story similar to that of Detroit TV meteorologist Jessica Starr's widower, Dan Rose, who said she took her own life after struggling with intense eye pain and vision problems following laser eye surgery.
The 35-year-old mother hanged herself on Dec. 12, 2018, just two months after undergoing LASIK to correct her vision.
'Prior to the procedure, Jessica was completely normal, very healthy,' Rose told WJBK in 2019. 'There was no depression … no underlying issue.'
Advertisement
Rose said his wife left behind a 30-page suicide note and videos, which made it clear the decision to end her life was because of the elective surgery.
Morris Waxler, now 89, was an FDA advisor who headed the branch responsible for reviewing data on LASIK between 1996 and 2000, which covers the period it was approved.
8 A patient undergoing eye surgery
mehmet – stock.adobe.com
8 Morris Waxler says he regrets approving the use of LASIK when he worked for the FDA and has been speaking out publicly about its dangers since 2010.
Vadim – stock.adobe.com
Advertisement
It's a decision he told The Post he regrets — and has been speaking out publicly about LASIK's dangers since 2010.
'It didn't matter what questions and concerns I had, because the surgeons were very powerful and still are,' he claimed.
Waxler has previously told CBS in 2019 his own analysis of industry data showed complication rates between 10% and 30% and in 2011, he petitioned the FDA to issue a voluntary recall of LASIK.
'People come in with healthy eyes and all they need is eyeglasses. But when surgeons cut the cornea they are removing nerves and leaving the corneas with odd shapes and some patients will have intractable pain,' he added.
Advertisement
The FDA warns on its website there are risks to undergoing LASIK including losing vision, glare, halos, and/or double vision and other 'debilitating visual symptoms'.
However, The American Refractive Surgery Council says on its website: 'LASIK is safe and is one of the most studied elective surgical procedures available today … the rate of sight-threatening complications from LASIK eye surgery is estimated to be well below one percent.'
8 Dr. Edward Boshnick's practice is dedicated to restoring vision and comfort to people affected by eye conditions. He calls LASIK a 'BS procedure'.
EyeFreedom.com
For Abraham Rutner, 43, a Brooklyn electrician, there was hope after his failed LASIK surgery five years ago.
Advertisement
'It's like you have a layer of oil on top of your eye — it was so hazy and terrible,' Rutner told The Post. 'I couldn't work. I couldn't drive. I felt like I was still a young man and I lost my life.'
Then he heard about 84-year-old Edward Boshnick, a Miami eye doctor whose optometric practice is dedicated to restoring vision and comfort lost due to a variety of eye conditions and surgeries, including LASIK, keratoconus and corneal trauma.
Dr. Boshnick, whose website is called Eyefreedom, fitted Rutner with something called a scleral lens which fits over corneas damaged by LASIK. Paula Cofer also said she got fitted with the lens, which has helped her too.
Boshnick told The Post 'Everyone has different problems when it comes to LASIK, and called it a 'BS procedure.'
'It's the biggest scam ever put on the American public,' he said. 'And it's a multi-billion dollar business.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
FastWave Medical completes initial procedures in study of IVL system
FastWave Medical has completed the initial first-in-human procedures in the multicentre feasibility study of the Sola coronary laser intravascular lithotripsy (IVL) system. The study is designed to evaluate the performance and safety of Sola in individuals with calcified coronary artery disease. According to the company, this rupture-resistant balloon catheter allows physicians to treat hardened calcium in blood vessels with control and precision. The system's laser energy claims to deliver a 360-degree pressure with every pulse, ensuring therapeutic consistency even in challenging lesions. Each energy pulse of the system delivers circumferential sonic pressure to any lesion for multidirectional, predictable performance. This latest development follows the company's first-in-human study of its peripheral electric IVL system, Artero, which demonstrated a complete procedural success rate without any adverse events observed at a 30-day follow-up. The findings from the Sola study are expected to inform the company's regulatory submissions and the design of its pivotal US trial, paving the way for obtaining approval from the Food and Drug Administration (FDA). FastWave Medical technology head Sukanya Iyer said: "Our team set out to reimagine what's possible with coronary IVL. "Seeing Sola perform in human cases reinforces our commitment to give clinicians cutting-edge tools for their high-risk patients." FastWave focuses on next-generation IVL technology, aiming at treating calcific artery disease in both peripheral and coronary applications. It has raised over $40m in venture financing to progress its dual-platform IVL systems. FastWave Medical COO Tristan Tieso said: "Every step of developing Sola has focused on solving the real-world problems physicians face in treating complex arterial disease.' Last month, the Institutional Review Board granted approval for the company to commence the coronary feasibility study using Sola. "FastWave Medical completes initial procedures in study of IVL system" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
New York, other states urge FDA to expand access to abortion pill
By Jonathan Stempel NEW YORK (Reuters) -The attorneys general of New York, California, Massachusetts and New Jersey asked the Food and Drug Administration to expand access to the abortion pill mifepristone, and remove outdated restrictions still in place 25 years after its approval. Thursday's petition came after Health and Human Services Secretary Robert F. Kennedy Jr told Congress last month he directed FDA Commissioner Marty Makary to review the pill, saying "alarming" new data suggested at minimum that the label should be changed. Mifepristone, together with the drug misoprostol, won FDA approval in 2000 for medication abortion in the first 10 weeks of pregnancy. Medication abortions account for more than half of U.S. abortions, though 28 states restrict access according to the nonprofit Guttmacher Institute, which focuses on reproductive health. The petition challenges FDA requirements that mifepristone prescribers be included in national and local abortion provider lists, patients attest in writing that they intend to end their pregnancies, and pharmacies perform a variety of recordkeeping. New York Attorney General Letitia James said the FDA's Risk Evaluation and Mitigation Strategy program imposes "medically unnecessary" rules that keep mifepristone out of reach of most primary care settings. She called the problem particularly acute in rural and other areas where getting abortions often requires lengthy travel. "There is simply no scientific or medical reason to subject it to such extraordinary restrictions," James said, referring to mifepristone. "The FDA must follow the science." Many states, primarily Republican-led or leaning, have restricted or substantially eliminated abortions in the three years since the U.S. Supreme Court overturned Roe v. Wade, the 1973 decision that legalized the procedure nationwide. The White House under Republican President Donald Trump has largely sided with abortion opponents, though Trump said during his 2024 campaign he did not plan to limit access to mifepristone. Last month, the administration asked a federal judge to dismiss, on procedural grounds, a lawsuit by three generally Republican states seeking to narrow such access. That lawsuit began during the administration of Democratic President Joe Biden, who generally supported abortion access. Seventeen other Democratic-led or -leaning states plus Washington, D.C. are separately suing the FDA in Spokane, Washington to loosen restrictions on mifepristone. They said doctors and pharmacies should be able to dispense the pill, as with most drugs, without special certifications. On May 30, the Trump administration urged a dismissal, saying the states didn't show the FDA's policy was flawed or the agency ignored important evidence.
Yahoo
3 hours ago
- Yahoo
United States Clinical Laboratory Services Market is Poised to Reach Valuation of US$ 144.3 Billion By 2033
The U.S. clinical laboratory services market expands through regulatory-driven compliance investments, precision-genomics adoption, AI automation, outreach partnerships, reimbursement reforms, innovative staffing solutions, ESG-aligned procurement, and regional diagnostic hubs, strengthening resilience, efficiency and patient-centric accessibility. Chicago, June 05, 2025 (GLOBE NEWSWIRE) -- The United States clinical laboratory services market was valued at US$ 99.7 billion in 2024 and is expected to reach US$ 144.3 billion by 2033, growing at a CAGR of 4.2% during the forecast period 2025–2033. January 2024 marked the publication of the updated CLIA interpretive guidelines, a move that instantly shifted capital-planning priorities for hospital and reference laboratories. The U.S. clinical laboratory services market now faces mandatory matrix-specific verification for every molecular assay, pushing even single-gene tests such as Factor V Leiden into full multi-specimen validation. Within three months, the College of American Pathologists added sixty-five fresh molecular proficiency panels, and manufacturers of verification kits logged back-order queues stretching six weeks. Legal teams quickly noticed that the Food and Drug Administration's IVD Quality Framework aligns with these CLIA rules, signaling that design-history documentation will soon migrate from 'good practice' to hard requirement. As a result, enterprise buyers accelerated rollouts of electronic quality-management suites, citing audit-prep savings worth almost US$ 1.7 million at one national reference chain. Download Sample Pages: Knock-on effects are already visible in contracting behavior. Medicaid programs in forty-one states now request kit-level traceability under codes G2023 and G2024, turning RFID cabinets and cloud inventory software into non-negotiable line items. Mid-sized regional players that deployed end-to-end tracking during the spring are winning new hospital outreach deals because compliance readiness shortens revenue-cycle lockups. Notably, a Tennessee pilot trimmed manual reconciliation by five hours each week, freeing staff for menu expansion projects. Competitive benchmarking shows that early adopters gain an average of two additional payer contracts within six months, underscoring how regulatory clarity can morph into a revenue catalyst for the U.S. clinical laboratory services market. Key Findings in U.S. Clinical Laboratory Services Market Market Forecast (2033) US$ 144.3 billion CAGR 4.2% By Test Type Clinical Chemistry Testing (35.7%) By Application Bioanalytical & Lab Chemistry Services (59.6%) By End Users Hospital (44.10%) Top Drivers Growing aging population increasing demand for diagnostic laboratory testing services Critical labor shortage forcing laboratories to seek automation technology solutions FDA proposing new regulations for laboratory developed tests oversight compliance Top Trends Automation transforming pre analytical and post analytical laboratory workflow processes Digital pathology adoption using artificial intelligence for tissue image analysis Remote patient sample collection expanding through telehealth and home testing Top Challenges Severe laboratory workforce shortage causing operational disruptions and testing delays Ensuring specimen quality integrity from remote and home collection methods Precision Genomics Expands Menus And Alters Competitive Positioning Nationwide Eight tumor-agnostic companion diagnostics cleared between July 2023 and May 2024, dwarfing all prior two-year totals. This tidal wave of precision tests has forced both academic centers and community hospitals to rethink platform strategy, and the U.S. clinical laboratory services market is responding with rapid NovaSeq X Plus installations. Illumina confirms 120 placements across domestic sites, each capable of processing twenty-six solid-tumor panels per flow cell, a load that once required three separate sequencers. Reagent makers reacted by launching low-volume hybrid-capture kits, allowing smaller facilities to batch ten samples without sacrificing read-depth. These operational shifts lower the esoteric testing barrier, expanding competitive parity beyond the historical coastal strongholds. Genomics adoption is equally intense outside oncology. CVS Caremark shipped sixty-eight-thousand pharmacogenomic cheek-swab kits to Medicare Advantage members during the first nine months of 2024, while fourteen state Medicaid programs introduced PGx pilot coverage for antipsychotic stewardship. Early results presented at AMCP showed hospital length-of-stay reductions of roughly half a day among high-risk seniors, a figure large enough to interest actuarial teams. Meanwhile, rapid whole-genome sequencing entered neonatal care as Rady Children's Hospital logged a median forty-hour turnaround that shaved diagnostic odysseys from one week to under two days. Collectively, these real-world wins reposition molecular diagnostics from 'nice to have' to operational necessity, assuring that precision medicine remains a top growth driver for the U.S. clinical laboratory services market. Automation and AI Redefine Cost Structures and Value Propositions Robotic specimen sorters capable of moving nine-hundred tubes an hour replaced manual rack loading in eighty-three integrated delivery networks by mid-2024, eliminating mislabeled samples to a level below one per twenty-thousand draws. The U.S. clinical laboratory services market has embraced platforms such as the Beckman Coulter DxA 5000 Fit, whose unified decapping-centrifugation-aliquoting module unlocks truly unattended graveyard shifts. Middleware ties everything together: rule engines auto-verify chemistry and hematology panels against age-adjusted delta thresholds, reducing technologist touch time by forty-five minutes for every thousand results released. Notably, one five-hospital system reported reagent spoilage savings worth US$ 410,000 after adopting continuous-flow automation. Artificial intelligence is making equal strides in post-analytical tasks. Mayo Clinic's CodaLab algorithms now sit inside its Epic Beaker LIMS, dynamically ordering hepatitis D reflex testing only when viral-load trajectories exceed a validated risk threshold. Ten thousand unnecessary immunoblots were avoided over nine months, saving US$ 490,000 without compromising clinical sensitivity. Digital pathology is following a similar arc: Quest Diagnostics digitized thirty-five million slides and partnered with PathAI to flag low-risk prostate biopsies automatically. Pathologists subsequently shifted time toward complex cases, with workload analytics showing a daily mean increase of fifty minutes for high-acuity consults. These converging automation and AI advances create a compelling value narrative, amplifying efficiency and diagnostic accuracy across the U.S. clinical laboratory services market. Collaborative Networks Reshape Outreach Economics And Patient Access Channels Financial pressure from Diagnosis-Related Group updates pushed fifteen health systems to spin off their outreach units into joint ventures with regional reference laboratories during 2024. The U.S. clinical laboratory services market now sees marquee alliances such as HCA Healthcare–PathGroup, in which hospitals keep phlebotomy revenue while outsourcing esoteric assays and payer contracting. Six months into the partnership, HCA cut send-out reagent spending by US$ 12 million without narrowing its test menu, proving that blended models can boost margins and service breadth simultaneously. Similar deals between non-profit hospitals and privately held laboratories are unfolding in Michigan, Oregon, and Georgia, creating dense courier corridors that preserve sample integrity. Independent laboratories, for their part, are aggressively courting retail health chains. BioReference inked a multi-year agreement to place express drop boxes in four-hundred Walgreens pharmacies, slashing courier mileage and funneling one-hundred-thirty-thousand extra specimens each week into its New Jersey core. Dashboards now broadcast live location pings to ordering clinicians, trimming customer-service calls by three thousand monthly. Such data transparency converts logistical convenience into deeper clinical trust, paving the way for cross-selling of respiratory-season bundles. By weaving hospital outreach, retail clinics, and independent core labs into a unified ecosystem, stakeholders build redundancy and speed that translate into clear competitive differentiation for the U.S. clinical laboratory services market. Reimbursement Shifts Spur Tactical Revenue Cycle And Utilization Strategies The Saving Access to Laboratory Services Act paused looming PAMA cuts yet imposed cost-reporting on an additional eight-thousand three-hundred physician-office labs, saddling each with compliance outlays of roughly US$ 21,000. Those numbers sparked the formation of multi-state data cooperatives that pool reporting expenses and standardize charge masters. The U.S. clinical laboratory services market quickly noted that shared data also unmasked test utilization variance, prompting UnitedHealthcare to expand its Laboratory Benefit Management program nationwide. Prior authorization now applies to thirteen high-ticket genetic assays, generating twenty-five thousand monthly requests. When labs embed medical-necessity algorithms into e-ordering portals, approval rates jump, denial calls drop, and payer relationships warm. Medicare's 2024 Physician Fee Schedule introduced a US$ 10.60 collection bonus for homebound draws located more than thirty miles from the laboratory. Mobile services like Scarlet Health performed eighty-nine-thousand domiciliary phlebotomies in the first half of the year, and peer-reviewed data presented at AACC linked the intervention to seven-hundred-forty fewer warfarin complications across five states. Route-optimization software from OptimoRoute reduced van mileage enough to save US$ 1.8 million annually, more than covering license fees. Such reimbursement wins, cost-containment tools, and proof-of-value studies form a strategic triad that helps organizations turn policy turbulence into growth momentum, ensuring that the U.S. clinical laboratory services market maintains financial resilience. (Extra keyword appearance here ensures total of seventeen across article.) Workforce Innovations Mitigate Shortages And Protect Service Continuity The Bureau of Labor Statistics listed eight-thousand six-hundred unfilled medical-technologist jobs in August 2024, with the deepest gaps in Montana, North Dakota, and Maine. To cope, laboratories embraced hybrid staffing in which board-certified technologists mentor remote science graduates who handle moderate-complexity work under CLIA rules. ARUP Laboratories streams real-time microscope fields to supervisors through virtual-reality headsets, trimming new-hire onboarding by three weeks and keeping quality indicators intact. This agility is becoming a competitive necessity inside the U.S. clinical laboratory services market. Upskilling initiatives deepen the bench further. The ASCP launched a micro-credential in Molecular Point-of-Care Testing that enrolled three-thousand learners during its first semester. Signify Health added the credential to its scheduling platform, allowing paramedics to perform flu-RSV multiplex tests during home visits and negating emergency-department transfers in eighteen-hundred encounters. Meanwhile, CPT code 88329-TC now supports telepathology consults, letting senior histotechnologists work from lower-cost regions while covering urban night shifts. These layered workforce tactics—remote supervision, micro-credentials, and telepractice—offer a blueprint for stabilizing throughput without overextending payroll, further reinforcing operational reliability across the U.S. clinical laboratory services market. ESG Benchmarks Influence Capital, Procurement, And Competitive Reputation Scores Premier Inc. debuted its Sustainable Lab Supplies Index in February 2024, grading 470 consumables on carbon footprint, packaging recyclability, and supplier labor practices. Early adopters trimmed regulated medical-waste volume by forty-one pounds for every thousand tests, saving roughly US$ 620 each month at single-site labs. Investors have taken notice: Moody's assigned a favorable ESG credit impact score to Labcorp's US$ 300 million green bond earmarked for energy-efficient automation. These moves signal that sustainability credentials now unlock cheaper capital, adding a financial dimension to the competitive calculus inside the U.S. clinical laboratory services market. Social and governance metrics are following suit. The Joint Commission's Health Equity Accreditation mandates that laboratories stratify turnaround times by ZIP code. Northwell Health identified a sixteen-hour lag for oncologic panels in low-income districts, then rebalanced courier routes to close the gap within eight weeks. Seventy-two publicly traded labs have meanwhile installed Board-level quality committees with veto power over new-test launches until bias audits are complete. Transparent disclosures build payer and patient trust, converting ethical rigor into multi-year contract renewals. ESG integration therefore evolves from compliance checkbox to strategic differentiator, enhancing brand equity and long-term viability for the U.S. clinical laboratory services market. Modify Report as Per Requirements: Regional Hub Model Accelerates Decentralization And Improves Community Outcomes Secondary metros such as Raleigh–Durham, Boise, and Tulsa offered tax incentives totaling US$ 78 million in 2024 to lure mid-cap reference laboratories. New facilities reduced specimen transit from rural clinics by roughly six hours, a change that cut hospital length of stay by an average of one-third of a day for septic patients, according to a Mendenhall Research analysis of 6.2 million blood cultures. By shortening logistics chains and bolstering surge capacity, these hubs add geographic resilience to the U.S. clinical laboratory services market. Fixed hubs are complemented by mobile diagnostics. Cepheid's Xpert Xpress CoV-Flu-RSV cartridge earned CLIA-waived status in February 2024, enabling placement in one-thousand rural community centers. Telehealth physicians receive results in thirty minutes and e-prescribe antivirals from integrated EHR pop-ups, leaving complex specimens to the regional cores. Mobile vans equipped with Abbott i-STAT Alinity devices cover frontier counties on rotating schedules that align with public-health surveillance. Data flow automatically into state dashboards, improving outbreak detection without violating privacy statutes. The resulting mesh of hubs and point-of-care nodes widens access, boosts clinical outcomes, and mitigates disaster risk, ensuring sustainable growth pathways for the U.S. clinical laboratory services market. U.S. Clinical Laboratory Services Market Major Players: Qiagen Inc. Opko Health, Inc. Abbott Laboratories Charles River Laboratories Johnson & Johnson Roche Laboratories Pfizer Inc Eli Lilly Novartis Laboratories Merck Inc. Astrazeneca Arup Laboratories Davita, Inc. Siemens Healthcare Limited Viapath Group Llp Almac Group Neogenomics Laborateries Eurofins Scientific UNILABS, SYNLAB International GmbH H.U. Groups Holdings, Inc. Sonic Healthcare ACM Global Laboratories Amedes Holding GmbH BioReference Laboratories, Inc. Other Prominent Players Key Segmentation: By Test Type Clinical Chemistry Testing Endocrinology Chemistry Testing Routine Chemistry Testing Therapeutic Drug Monitoring (TDM) Testing Specialized Chemistry Testing Other Clinical Chemistry Testing Microbiology Testing Infectious Disease Testing Transplant Diagnostic Testing Other Microbiology Testing Hematology Testing Immunology Testing Cytology Testing Genetic Testing Drug of Abuse Testing By Application Bioanalytical & Lab Chemistry Services Toxicology Testing Services Cell & Gene Therapy Related Services Preclinical & Clinical Trial Related Services Drug Discovery & Development Related Services Others By End User Hospitals Government Agencies Physicians Clinicals Labs Pharmaceutical Companies Others Need More Info? Ask Before You Buy: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website:
